Autopsy report · NCT04891718

CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia

“Termination by pharmaceutical sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Early Phase 1

Sponsor

Presage Biosciences

Sponsor type

Industry

Conditions

Solid Tumour

Interventions

MVC-101; Nivolumab; MVC-101 + Nivolumab

Participants

0

Sites

3

Countries

Australia

Trials that died the same way

• Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia
  “Termination of the clinical trial by sponsor.” (79% match in meaning)
• Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
  “Sponsor requested termination” (77% match in meaning)
• Evaluation of Cranioplasty Using Native Bone Autograft Versus Synthetic Bone Allograft
  “Sponsor termination” (77% match in meaning)
• Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
  “Sponsor's discretion to termination due to business decision.” (75% match in meaning)
• A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer
  “Trial was terminated to allow sponsors to evaluate the future development of the drug program” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.